School of Clinical Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China,
Department of Chinese Medicine, The Fourth People's Hospital of Chengdu, Chengdu, China.
Gynecol Obstet Invest. 2021;86(3):218-230. doi: 10.1159/000515893. Epub 2021 May 12.
This systematic and meta-analysis was conducted to evaluate the efficacy and safety of insulin, metformin, and glyburide on perinatal complications for gestational diabetes mellitus (GDM).
Medline (PubMed), EMBASE, The Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials [CENTRAL], and Cochrane Methodology Register), Web of Science (Science and Social Science Citation Index), and ClinicalTrials (Clinicaltrials.gov) were searched, as well as manual searching. We included randomized controlled trials comparing efficacy and safety of metformin versus glyburide, metformin versus insulin, and glyburide versus insulin in patients with GDM.
We included 32 articles including 5,964 patients published from inception to July 2020. Compared with insulin, metformin was more effective at lower incidence of macrosomia (RR: 0.66, 95% CI: 0.50-0.88, p = 0.005), lower incidence of neonatal intensive care unit admission (RR: 0.78, 95% CI: 0.67-0.91, p = 0.002), less neonatal hypoglycemia (RR: 0.67, 95% CI: 0.56-0.80, p < 0.0001), decreased birth weight (BW) (SMD: -0.37, 95% CI: -0.62 to -0.12, p = 0.004), lower incidence of large for gestational age (RR: 0.76, 95% CI: 0.50-0.90, p = 0.002), shorter gestation age at delivery (MD: -0.22, 95% CI: -0.34 to -0.10, p = 0.0002), lower maternal weight gain (MD: -1.41, 95% CI: -2.28 to -0.55, p = 0.001), less incidence of caesarean section delivery (RR: 0.86, 95% CI: 0.78-0.95, p = 0.0004), lower maternal postprandial blood glucose (SMD: -0.41, 95% CI: -0.72 to -0.11, p = 0.008), and lower incidence of pregnancy-induced hypertension (RR: 0.47, 95% CI: 0.27-0.83, p = 0.01). However, glyburide, compared with insulin, was associated with higher BW (MD: 54.95, 95% CI: 3.87-106.03, p = 0.03) and increased the incidence of neonatal hypoglycemia (RR: 1.52, 95% CI: 1.12-2.07, p = 0.007). Meanwhile, compared to glyburide, metformin was associated with higher maternal fasting blood glucose (SMD: 0.20, 95% CI: 0.05-0.36, p = 0.01) and lower incidence of induction of labor (RR: 0.76, 95% CI: 0.59-0.97, p = 0.03).
This review suggests that metformin can decrease the incidence of perinatal complications, and it should be considered as a generally safe alternative to insulin.
本系统评价和荟萃分析旨在评估胰岛素、二甲双胍和格列吡嗪治疗妊娠期糖尿病(GDM)围产期并发症的疗效和安全性。
检索 Medline(PubMed)、EMBASE、The Cochrane Library(Cochrane 系统评价数据库、Cochrane 中心对照试验注册库、Cochrane 方法学登记册)、Web of Science(科学和社会科学引文索引)和 ClinicalTrials(Clinicaltrials.gov),并进行手动检索。我们纳入了比较二甲双胍与格列吡嗪、二甲双胍与胰岛素、格列吡嗪与胰岛素在 GDM 患者中的疗效和安全性的随机对照试验。
我们纳入了 32 篇文章,共包括 5964 名患者,这些文章发表于研究开始至 2020 年 7 月。与胰岛素相比,二甲双胍在降低巨大儿发生率(RR:0.66,95%CI:0.50-0.88,p=0.005)、新生儿重症监护病房入院率(RR:0.78,95%CI:0.67-0.91,p=0.002)、新生儿低血糖发生率(RR:0.67,95%CI:0.56-0.80,p<0.0001)、降低出生体重(SMD:-0.37,95%CI:-0.62 至 -0.12,p=0.004)、降低巨大儿发生率(RR:0.76,95%CI:0.50-0.90,p=0.002)、缩短分娩时的胎龄(MD:-0.22,95%CI:-0.34 至 -0.10,p=0.0002)、降低母亲体重增加(MD:-1.41,95%CI:-2.28 至 -0.55,p=0.001)、降低剖宫产分娩率(RR:0.86,95%CI:0.78-0.95,p=0.0004)、降低母亲餐后血糖(SMD:-0.41,95%CI:-0.72 至 -0.11,p=0.008)和降低妊娠高血压发生率(RR:0.47,95%CI:0.27-0.83,p=0.01)方面更有效。然而,与胰岛素相比,格列吡嗪与较高的体重(MD:54.95,95%CI:3.87-106.03,p=0.03)和增加新生儿低血糖发生率(RR:1.52,95%CI:1.12-2.07,p=0.007)相关。同时,与格列吡嗪相比,二甲双胍与较高的母亲空腹血糖(SMD:0.20,95%CI:0.05-0.36,p=0.01)和降低引产发生率(RR:0.76,95%CI:0.59-0.97,p=0.03)相关。
本综述表明,二甲双胍可以降低围产期并发症的发生率,应考虑将其作为胰岛素的一种更安全的替代药物。